Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (150)	12/9/2003 8:13:47 PM
From: scaram(o)uche	Respond to of 411

Thanks, for finding that. It clarifies that weird quote from Borer, quite well.......... While the committee settled on restricted use in resistant patients as a more appropriate indication for Ranexa, members pointed out that the drug had not been studied in that group of patients and therefore advised that a new study would have to be performed.

To: tom pope who wrote (150)	12/9/2003 8:39:53 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 411

>> (maybe I'll get my "very small position" tomorrow) It just sounds like expensive road blocks. << Yeah, I have similar sentiments. The Bull's "But"..... assume burn this quarter equivalent to last, and assume that it's already all gone...... $15/share, cash, closed at 2.3X book yesterday. Pharmas wouldn't blink an eye at taking on discounted debt, with or without a pipeline or valuable I.P. That's the basic to return to, over and over, in biotech investing..... "what would a pharma pay for it?" Shut the doors today, what would someone pay for it? Should you ignore burn? No, that would be simple minded and/or just plain dumb. But, should one let the shorts and burn scare you to the point of not recognizing a bargain? Miljenko made the correct call, and he may be correct about it going to single digits. But it's worth lots more and -- if drug development logic prevailed -- IMO shouldn't go there. Wyeth to offer $850 mln in convertibles Tuesday December 9, 5:33 pm ET biz.yahoo.com